Hemant Surgical Industries Ltd.
Hemant Surgical Industries Ltd. Fundamental Analysis
Hemant Surgical Industries Ltd. (HSIL.BO) shows weak financial fundamentals with a PE ratio of 30.19, profit margin of 8.43%, and ROE of 11.08%. The company generates $1.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -5.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze HSIL.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakHSIL.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateHSIL.BO shows balanced valuation metrics.
Growth Score
ModerateHSIL.BO shows steady but slowing expansion.
Financial Health Score
ExcellentHSIL.BO maintains a strong and stable balance sheet.
Profitability Score
WeakHSIL.BO struggles to sustain strong margins.
Key Financial Metrics
Is HSIL.BO Expensive or Cheap?
P/E Ratio
HSIL.BO trades at 30.19 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, HSIL.BO's PEG of 1.11 indicates fair valuation.
Price to Book
The market values Hemant Surgical Industries Ltd. at 2.53 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 18.29 times EBITDA. This signals the market has high growth expectations.
How Well Does HSIL.BO Make Money?
Net Profit Margin
For every $100 in sales, Hemant Surgical Industries Ltd. keeps $8.43 as profit after all expenses.
Operating Margin
Core operations generate 9.50 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.08 in profit for every $100 of shareholder equity.
ROA
Hemant Surgical Industries Ltd. generates $4.80 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Hemant Surgical Industries Ltd. generates limited operating cash flow of $-75.96M, signaling weaker underlying cash strength.
Free Cash Flow
Hemant Surgical Industries Ltd. generates weak or negative free cash flow of $-337.55M, restricting financial flexibility.
FCF Per Share
Each share generates $-31.84 in free cash annually.
FCF Yield
HSIL.BO converts -10.84% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
30.19
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.11
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.53
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.55
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.43
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.11
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How HSIL.BO Stacks Against Its Sector Peers
| Metric | HSIL.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 30.19 | 29.45 | Neutral |
| ROE | 11.08% | 779.00% | Weak |
| Net Margin | 8.43% | -24936.00% (disorted) | Weak |
| Debt/Equity | 0.43 | 0.26 | Weak (High Leverage) |
| Current Ratio | 2.11 | 4.65 | Strong Liquidity |
| ROA | 4.80% | -19344.00% (disorted) | Weak |
HSIL.BO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Hemant Surgical Industries Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation